US 9,808,522 B2
Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
Andreas Zirlik, Freiburg (DE); Dennis Wolf, Freiburg (DE); and Karlheinz Peter, Melbourne (AU)
Assigned to UNIVERSITATSKLINIKUM FREIBURG, Freiburg (DE); and BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., Melbourne (AU)
Appl. No. 13/880,498
Filed by Andreas Zirlik, Freiburg (DE); Dennis Wolf, Freiburg (DE); and Karlheinz Peter, Melbourne (AU)
PCT Filed Aug. 17, 2011, PCT No. PCT/EP2011/064132
§ 371(c)(1), (2), (4) Date Jun. 28, 2013,
PCT Pub. No. WO2012/052205, PCT Pub. Date Apr. 26, 2012.
Claims priority of application No. 10188325 (EP), filed on Oct. 21, 2010.
Prior Publication US 2014/0147445 A1, May 29, 2014
Int. Cl. A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 38/08 (2006.01); A61K 38/10 (2006.01); A61K 38/12 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 38/12 (2013.01); A61K 38/1709 (2013.01); C07K 16/241 (2013.01); C07K 16/2845 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01)] 4 Claims
 
1. A pharmaceutical composition comprising a chemically and/or structurally modified polypeptide having the amino acid sequence SEQ ID NO:1, wherein the polypeptide has not more than 15 amino acids, wherein the chemically and/or structurally modified polypeptide is stabilized against degradation in a patient, and wherein SEQ ID NO:1 is capable of inhibiting the binding of Mac-1 to CD40L, and wherein a leucine residue is replaced by an isoleucine residue or by an arginine residue in SEQ ID NO:1.